Sorrento Therapeutics, Inc

(NASDAQ:SRNE)

Latest On Sorrento Therapeutics, Inc (SRNE):

Date/Time Type Description Signal Details
2023-02-22 17:46 ESTNewsAn Update On Sorrento: Hitting Rock Bottom And Finding A ShovelN/A
2023-02-14 00:50 ESTNewsSorrento sheds 60% after bankruptcy filing (update)N/A
2023-02-14 00:50 ESTNewsSorrento Therapeutics subsidiary Scilex not a part of Chapter 11 bankruptcy filingN/A
2023-02-13 11:25 ESTNewsSorrento sheds 28% after bankruptcy filingN/A
2023-01-28 01:58 ESTNewsSorrento Therapeutics: Dilution Damocles Sword Outweighs Potential ReturnsN/A
2023-01-24 19:38 ESTNewsA SPAC, Spinoff, And Short Squeeze Walk Into A BarN/A
2022-12-07 01:28 ESTNewsFDA clears Sorrento to start trials with mRNA vaccine candidate against Omicron variantsN/A
2022-11-30 06:19 ESTNewsSorrento posts Phase 1 data for oral COVID therapyN/A
2022-11-10 05:56 ESTNewsSorrento: Limited Potential, High Management Compensation, Complicated LawsuitsN/A
2022-11-08 00:51 ESTNewsSorrento Therapeutics: Down The Rabbit HoleN/A
2022-09-30 23:23 ESTNewsSorrento in credit agreement with B. Riley for $41.7MN/A
2022-09-29 15:42 ESTNewsSorrento unit Scilex pre-emptively pays off remaining notes for $39.7MN/A
2022-09-15 22:23 ESTNewsSorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trialN/A
2022-08-31 19:12 ESTNewsSorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103N/A
2022-08-31 19:12 ESTNewsHot Stocks: SRNE gains on FDA news, CHS rises on earnings, HPQ dips on Q3 estimates, and OSCR fallsN/A
2022-08-23 17:07 ESTNewsSorrento achieves positive results in pivotal trial for abivertinib in NSCLCN/A
2022-08-20 10:25 ESTNewsSorrento trial for oral COVID-19 therapy granted regulatory nod in ChinaN/A
2022-08-20 10:24 ESTNewsSorrento Therapeutics: COVISTIX Sales Are Lagging BehindN/A
2022-08-18 00:36 ESTNewsSorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH TradingN/A
2022-07-19 22:36 ESTNewsSorrento rises as FDA clears Phase 1 trial for COVID-19 therapeuticN/A
2022-07-15 03:36 ESTNewsSorrento Therapeutics: The EnigmaN/A
2022-07-07 18:44 ESTNewsSorrento Therapeutics subsidiary Scilex to acquire Ancora MedicalN/A
2022-06-14 22:43 ESTNewsSorrento unit Scilex gets license to commercialize Romeg's gout treatment GloperbaN/A
2022-06-04 06:59 ESTNewsSorrento's Scilex repurchases $41.4M notes ahead of going public with SPAC Vickers VantageN/A
2022-05-19 08:38 ESTNewsSorrento' unit Scilex begins dosing in mid-stage study of SP-103 for lower back painN/A
2022-05-17 17:21 ESTNewsSorrento stock rises after FDA gives nod to begin phase 2 study of abivertinib to treat prostate cancerN/A
2022-04-28 19:36 ESTNewsScilex, part of Sorrento Therapeutics names new CFON/A
2022-04-26 02:49 ESTNewsSorrento gets FDA nod to start early-stage trial for intravenous COVID-19 therapyN/A
2022-04-26 02:49 ESTNewsSorrento subsidiary Scilex expands distribution network to national, regional wholesalersN/A
2022-03-31 18:26 ESTNewsSorrento granted FDA clearance to start late-stage trial for COVID-19 therapyN/A
2022-03-28 00:53 ESTNewsMorgan Stanley projects about a third of biotechs will need financing in 2022N/A
2022-03-26 11:31 ESTNewsSorrento subsidiary Scilex to enter deal for $5 billion equity financingN/A
2022-03-19 07:16 ESTNewsSorrento Therapeutics sciatica pain treatment meets primary endpoint in phase 3 trialN/A
2022-03-19 07:16 ESTNewsSorrento subsidiary Scilex to go public in SPAC merger with Vickers VantageN/A
2022-03-16 11:56 ESTNewsSorrento Therapeutics: Sales Are Up But EY Identifies Internal Control IssuesN/A
2022-03-02 23:31 ESTNewsSorrento granted FDA nod to start clinical trial for intranasal COVID-19 therapyN/A
2022-02-22 10:45 ESTNewsSorrento' COVISHIELD shows neutralizing activity vs Omicron subvariantsN/A
2022-02-18 01:48 ESTNewsSorrento acquires a majority stake in FortuneBio to meet demand for rapid COVID-19 testN/A
2022-01-28 13:44 ESTNewsSorrento rises 7% as STI-1558 neutralizes omicron in cell-based testsN/A
2022-01-24 10:30 ESTNewsSorrento receives purchase order for 10M Covistix tests from its subsidiary for delivery in MexicoN/A
2022-01-20 09:47 ESTNewsSorrento says COVID-19 antibody neutralized Omicron in lab studiesN/A
2022-01-19 17:56 ESTNewsSorrento issues enrollment update on mid-stage trials for COVID-19 antibodyN/A
2022-01-19 02:50 ESTNewsSorrento gets Brazilian regulator nod to begin phase 2 trial of COVI-MSC for COVID-19N/A
2022-01-13 21:15 ESTNewsSorrento to provide COVISTIX rapid COVID-19 tests to Mexico City governmentN/A
2022-01-08 03:55 ESTNewsSorrento Therapeutics announces unexpected death of CFO Najjam AsgharN/A
2021-12-27 20:10 ESTNewsSorrento Therapeutics' Mexico executes second contract for sale of 10M Covistix testsN/A
2021-12-27 20:10 ESTNewsSorrento's COVID-19 rapid antigen test detects Omicron variantN/A
2021-12-20 14:39 ESTNewsSorrento granted FDA OK for IND to conduct trial of oncolytic virus candidateN/A
2021-12-10 02:51 ESTNewsSorrento subsidiary reports positive SP-102 results from late-stage sciatica pain studyN/A
2021-12-06 22:33 ESTNewsSorrento reports publication of a series of SARS-CoV-2 MPro inhibitors for treatment of COVID-19N/A

About Sorrento Therapeutics, Inc (SRNE):

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

SRNE Quotes by TradingView

See Advanced Chart

General

  • Name Sorrento Therapeutics, Inc
  • Symbol SRNE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 502
  • Last Split Factor1:25
  • Last Split Date2013-08-01
  • Fiscal Year EndDecember
  • IPO Date2010-01-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.sorrentotherapeutics.com
View More

Valuation

  • Forward PE 1.18
  • Price/Sales (Trailing 12 Mt.) 57.48
  • Price/Book (Most Recent Quarter) 17.01
  • Enterprise Value Revenue 73.06
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $1.90
  • Next Year EPS Estimate $2.34
  • Next Quarter EPS Estimate $0.36
  • Operating Margin -504%
  • Return on Assets -23%
  • Return on Equity -362%
  • Revenue 39.99 million
  • Earnings Per Share -$2.40
  • Revenue Per Share $0.17
  • Gross Profit -81294000
  • Quarterly Earnings Growth -11.7%
View More

Highlights

  • Market Capitalization 2.8 billion
  • EBITDA -169703008
  • PEG Ratio -0.07
  • Analyst Target Price $28
  • Book Value Per Share $0.62
View More

Share Statistics

  • Shares Outstanding 280.86 million
  • Shares Float 242.72 million
  • % Held by Insiders 1571%
  • % Held by Institutions 27.98%
  • Shares Short 56.94 million
  • Shares Short Prior Month 64.15 million
  • Short Ratio 2.45
  • Short % of Float 21%
  • Short % of Shares Outstanding 20%
View More

Technicals

  • Beta 2.34
  • 52 Week High $19.39
  • 52 Week Low $1.7
  • 50 Day Moving Average 12.07
  • 200 Day Moving Average 9.17
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Sorrento Therapeutics, Inc (SRNE) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Sorrento Therapeutics, Inc (SRNE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-19$N/A-$0.25-$0.23-7.16%
2020-09-302020-11-09$11.75 million-$0.33-$0.16-106.25%
2020-06-302020-08-04$N/A-$0.36-$0.22-63.64%
2020-03-312020-05-11$7.72 million-$0.36-$0.20-80%
2019-12-312020-03-03$13.03 million-$0.20-$0.4151.22%
2019-09-302019-11-12$5.78 million-$0.50-$0.42-19.05%
2019-06-302019-08-09$6.48 million-$0.46-$0.40-15%
2019-03-312019-05-15$6.14 million-$0.88-$0.35-153.82%
2018-12-312019-03-15$6.93 million-$0.40-$0.27-48.15%
2018-09-302018-11-09$4.11 million-$0.40-$0.19-114.25%
2018-06-302018-08-09$3.91 million-$0.73-$0.20-265%
2018-03-312018-05-10$6.25 million-$0.38-$0.17-130.3%
2017-12-312018-03-16$20.41 million$0.55-$0.14492.86%
2017-09-302017-11-09$121.91 million$0.44-$0.23291.3%
2017-06-302017-08-09$4.67 million-$0.20-$0.3441.18%
2017-03-312017-05-15$4.87 million-$0.45-$0.33-36.36%
2016-12-312017-03-22$4.02 million-$0.30-$0.27-11.11%
2016-09-302016-11-09$2.24 million$0.22-$0.21204.76%
2016-06-302016-08-08$902000-$0.97-$0.22-334.39%
2016-03-312016-05-10$988000-$0.48-$0.37-28.58%
2015-12-312016-03-15$1.34 million-$0.62-$0.36-70.66%
2015-09-302015-11-16$1.1 million-$0.03-$0.3591.43%
2015-06-302015-08-07$1.17 million-$0.30-$0.25-20%
2015-03-312015-05-05$977000-$0.29-$0.09-222.22%
2014-12-312015-03-16$798000-$0.28-$0.27-3.7%
2014-09-302014-11-04$1.28 million-$0.27-$0.3215.63%
2014-06-302014-08-06$775000-$0.33-$0.3813.16%
2014-03-312014-04-01$976000-$0.66-$0.17-288.24%
2013-12-312014-03-31$101000-$0.66-$0.17-288.24%
2013-09-302013-11-14$83000-$0.24-$0.19-26.32%
2013-06-302013-08-28$142000-$0.35
2013-03-312013-05-29$134000-$0.20
2012-12-312012-12-31$122000-$0.15
2012-09-302012-09-30$135000-$0.10
2012-06-302012-06-30$217000-$0.08
2012-03-312012-03-31$110000-$0.09
2011-12-312011-12-31$128000-$0.08
2011-09-302011-09-30$91000-$0.07
2011-06-302011-06-30$75000-$0.11
2011-03-312011-03-31$235000-$0.07
2010-12-312010-12-31$512000-$0.02
2010-09-302010-09-30$114000-$0.05
2010-06-302010-06-30$56000-$0.07
2010-03-312010-03-31$N/A-$0.07
2009-09-302009-09-30$N/A-$0.03

Sorrento Therapeutics, Inc (SRNE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Sorrento Therapeutics, Inc (SRNE) Chart:

Sorrento Therapeutics, Inc (SRNE) News:

Below you will find a list of latest news for Sorrento Therapeutics, Inc (SRNE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Sorrento Therapeutics, Inc (SRNE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest SRNE Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$1.405
Jun 13, 2022 7:59 PM EST13$1.41
Jun 13, 2022 7:59 PM EST89$1.41
Jun 13, 2022 7:59 PM EST20$1.405
Jun 13, 2022 7:59 PM EST153$1.41

Sorrento Therapeutics, Inc (SRNE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920079748/0001104659-20-079748-index.htm
2018-12-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/850261/000000000018038253/0000000000-18-038253-index.htm
2019-02-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/850261/000000000019002564/0000000000-19-002564-index.htm
2019-06-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/850261/000000000019010240/0000000000-19-010240-index.htm
2019-12-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/850261/000000000019016105/0000000000-19-016105-index.htm
2020-01-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/850261/000000000020000792/0000000000-20-000792-index.htm
2020-03-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/850261/000000000020002377/0000000000-20-002377-index.htm
2020-10-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/850261/000000000020009368/0000000000-20-009368-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000021545719006731/0000215457-19-006731-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000083423720006706/0000834237-20-006706-index.htm
2020-04-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000083423720009369/0000834237-20-009369-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026118000045/0000850261-18-000045-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026118000046/0000850261-18-000046-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026118000047/0000850261-18-000047-index.htm
2019-03-1510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/850261/000085026119000002/0000850261-19-000002-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000010/0000850261-19-000010-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000011/0000850261-19-000011-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000012/0000850261-19-000012-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000013/0000850261-19-000013-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000014/0000850261-19-000014-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000015/0000850261-19-000015-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000016/0000850261-19-000016-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/850261/000085026119000018/0000850261-19-000018-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/850261/000085026119000020/0000850261-19-000020-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000085026119000024/0000850261-19-000024-index.htm
2019-08-02PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000027/0000850261-19-000027-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/850261/000085026119000029/0000850261-19-000029-index.htm
2019-08-14DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000031/0000850261-19-000031-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/850261/000085026119000036/0000850261-19-000036-index.htm
2019-11-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000037/0000850261-19-000037-index.htm
2019-11-22S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000085026119000041/0000850261-19-000041-index.htm
2019-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000043/0000850261-19-000043-index.htm
2019-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000045/0000850261-19-000045-index.htm
2019-12-17S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000085026119000054/0000850261-19-000054-index.htm
2019-12-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000056/0000850261-19-000056-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026119000058/0000850261-19-000058-index.htm
2020-01-07S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000085026120000003/0000850261-20-000003-index.htm
2020-01-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000085026120000006/0000850261-20-000006-index.htm
2020-01-17S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000085026120000011/0000850261-20-000011-index.htm
2020-01-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000085026120000014/0000850261-20-000014-index.htm
2020-01-23S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000085026120000018/0000850261-20-000018-index.htm
2020-01-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000085026120000020/0000850261-20-000020-index.htm
2020-01-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000085026120000022/0000850261-20-000022-index.htm
2020-03-0310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/850261/000085026120000027/0000850261-20-000027-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000029/0000850261-20-000029-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000039/0000850261-20-000039-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000040/0000850261-20-000040-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000041/0000850261-20-000041-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000042/0000850261-20-000042-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000043/0000850261-20-000043-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000044/0000850261-20-000044-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000045/0000850261-20-000045-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000046/0000850261-20-000046-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000047/0000850261-20-000047-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000049/0000850261-20-000049-index.htm
2020-08-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000085026120000051/0000850261-20-000051-index.htm
2019-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000110465919007632/0001104659-19-007632-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465919066806/0001104659-19-066806-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465919070778/0001104659-19-070778-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465919074985/0001104659-19-074985-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920002827/0001104659-20-002827-index.htm
2020-01-17S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000110465920005175/0001104659-20-005175-index.htm
2020-01-24S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000110465920006741/0001104659-20-006741-index.htm
2020-01-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920006911/0001104659-20-006911-index.htm
2020-01-29424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000110465920008107/0001104659-20-008107-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000110465920013641/0001104659-20-013641-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000110465920013642/0001104659-20-013642-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000110465920013643/0001104659-20-013643-index.htm
2020-02-11424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000110465920014732/0001104659-20-014732-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920014735/0001104659-20-014735-index.htm
2020-02-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000110465920019333/0001104659-20-019333-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000110465920020588/0001104659-20-020588-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920025616/0001104659-20-025616-index.htm
2020-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920030232/0001104659-20-030232-index.htm
2020-03-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000110465920032657/0001104659-20-032657-index.htm
2020-03-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000110465920035274/0001104659-20-035274-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920036316/0001104659-20-036316-index.htm
2020-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920040756/0001104659-20-040756-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920051638/0001104659-20-051638-index.htm
2020-04-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000110465920051641/0001104659-20-051641-index.htm
2020-04-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000110465920051642/0001104659-20-051642-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920062404/0001104659-20-062404-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920064520/0001104659-20-064520-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920070100/0001104659-20-070100-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920072906/0001104659-20-072906-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920079044/0001104659-20-079044-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920079748/0001104659-20-079748-index.htm
2020-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920084541/0001104659-20-084541-index.htm
2020-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920084669/0001104659-20-084669-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920086206/0001104659-20-086206-index.htm
2020-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920087624/0001104659-20-087624-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920092149/0001104659-20-092149-index.htm
2020-08-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/850261/000110465920092159/0001104659-20-092159-index.htm
2020-08-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920096566/0001104659-20-096566-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920097286/0001104659-20-097286-index.htm
2020-09-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920101663/0001104659-20-101663-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920104550/0001104659-20-104550-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920105841/0001104659-20-105841-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920109417/0001104659-20-109417-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920112830/0001104659-20-112830-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920114032/0001104659-20-114032-index.htm
2020-10-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920114782/0001104659-20-114782-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/850261/000110465920116285/0001104659-20-116285-index.htm
2020-10-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920116491/0001104659-20-116491-index.htm
2020-10-22S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/850261/000110465920117211/0001104659-20-117211-index.htm
2020-10-22S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/850261/000110465920117212/0001104659-20-117212-index.htm
2020-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920118549/0001104659-20-118549-index.htm
2020-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000110465920119284/0001104659-20-119284-index.htm
2018-12-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000114420418064341/0001144204-18-064341-index.htm
2018-12-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000114420418064349/0001144204-18-064349-index.htm
2018-12-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000114420418064351/0001144204-18-064351-index.htm
2018-12-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000114420418064353/0001144204-18-064353-index.htm
2018-12-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000114420418065386/0001144204-18-065386-index.htm
2018-12-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000114420418066068/0001144204-18-066068-index.htm
2019-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419002174/0001144204-19-002174-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419002490/0001144204-19-002490-index.htm
2019-02-11S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000114420419006308/0001144204-19-006308-index.htm
2019-02-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419008403/0001144204-19-008403-index.htm
2019-03-01NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/850261/000114420419011673/0001144204-19-011673-index.htm
2019-03-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000114420419014095/0001144204-19-014095-index.htm
2019-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419015420/0001144204-19-015420-index.htm
2019-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419017891/0001144204-19-017891-index.htm
2019-04-038-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419017950/0001144204-19-017950-index.htm
2019-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419019578/0001144204-19-019578-index.htm
2019-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419019792/0001144204-19-019792-index.htm
2019-05-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419023619/0001144204-19-023619-index.htm
2019-05-03S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000114420419023679/0001144204-19-023679-index.htm
2019-05-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000114420419023686/0001144204-19-023686-index.htm
2019-05-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000114420419024270/0001144204-19-024270-index.htm
2019-05-10NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/850261/000114420419025257/0001144204-19-025257-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419025610/0001144204-19-025610-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419027535/0001144204-19-027535-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419029587/0001144204-19-029587-index.htm
2019-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419029805/0001144204-19-029805-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419030633/0001144204-19-030633-index.htm
2019-06-17S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000114420419031177/0001144204-19-031177-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419031184/0001144204-19-031184-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419031390/0001144204-19-031390-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419031590/0001144204-19-031590-index.htm
2019-06-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000114420419032710/0001144204-19-032710-index.htm
2019-06-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000114420419032855/0001144204-19-032855-index.htm
2019-06-28FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/850261/000114420419032856/0001144204-19-032856-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419033099/0001144204-19-033099-index.htm
2019-06-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000114420419033102/0001144204-19-033102-index.htm
2019-07-01424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000114420419033412/0001144204-19-033412-index.htm
2019-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419033529/0001144204-19-033529-index.htm
2019-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419039076/0001144204-19-039076-index.htm
2019-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419039079/0001144204-19-039079-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419045535/0001144204-19-045535-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419045544/0001144204-19-045544-index.htm
2019-10-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000114420419046758/0001144204-19-046758-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419046763/0001144204-19-046763-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419046767/0001144204-19-046767-index.htm
2019-10-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/850261/000114420419047669/0001144204-19-047669-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419047672/0001144204-19-047672-index.htm
2019-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000114420419047745/0001144204-19-047745-index.htm
2019-05-09SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/850261/000119312519143162/0001193125-19-143162-index.htm
2019-09-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/850261/000119312519254842/0001193125-19-254842-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/850261/000156459020024153/0001564590-20-024153-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/850261/000156459020036142/0001564590-20-036142-index.htm
2020-08-21PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/850261/000156459020040973/0001564590-20-040973-index.htm
2020-09-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/850261/000156459020042218/0001564590-20-042218-index.htm
2020-09-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/850261/000156459020044814/0001564590-20-044814-index.htm
2020-09-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000156459020045352/0001564590-20-045352-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000156459020045743/0001564590-20-045743-index.htm
2020-10-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/850261/000156459020045928/0001564590-20-045928-index.htm
2020-10-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/850261/000156459020046119/0001564590-20-046119-index.htm
2020-10-08424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000156459020046132/0001564590-20-046132-index.htm
2020-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000156459020046179/0001564590-20-046179-index.htm
2020-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/850261/000156459020046664/0001564590-20-046664-index.htm
2020-10-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/850261/000156459020047094/0001564590-20-047094-index.htm
2018-12-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999518003214/9999999995-18-003214-index.htm
2019-05-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999519001030/9999999995-19-001030-index.htm
2019-07-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999519001488/9999999995-19-001488-index.htm
2020-01-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999520000141/9999999995-20-000141-index.htm
2020-01-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999520000186/9999999995-20-000186-index.htm
2020-03-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999520000602/9999999995-20-000602-index.htm
2020-10-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999520002796/9999999995-20-002796-index.htm
2020-10-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/850261/999999999520002922/9999999995-20-002922-index.htm
2018-12-06CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/850261/999999999718009350/9999999997-18-009350-index.htm
2019-05-14CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/850261/999999999719004342/9999999997-19-004342-index.htm
2019-06-11CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/850261/999999999719005423/9999999997-19-005423-index.htm
2019-08-14CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/850261/999999999719006483/9999999997-19-006483-index.htm
2019-10-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/850261/999999999719007191/9999999997-19-007191-index.htm
2019-11-13CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/850261/999999999719007555/9999999997-19-007555-index.htm
2020-02-07SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/850261/999999999720000596/9999999997-20-000596-index.htm
2020-02-27SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/850261/999999999720001052/9999999997-20-001052-index.htm

Sorrento Therapeutics, Inc (SRNE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sorrento Therapeutics, Inc (SRNE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1571%
Institutional Ownership: 2798%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-05Robin L SmithDirectorBuy40,000.002.2790,896.0060,000.00https://www.sec.gov/Archives/edgar/data/850261/000085026120000029/0000850261-20-000029-index.htm